List view / Grid view
12 November 2014 | By Novartis
Novartis announced that, through Power of One, enough funds have been raised to deliver three million antimalarial treatments for children in Zambia...
11 November 2014 | By Mundipharma
New research unveiled by Mundipharma highlights inconsistencies in health economic models and measurement methods used in clinical trials for pain therapies...
The newest GLP-1 receptor agonist treatment option to help improve glycemic control type 2 diabetes in adults is now available in U.S. pharmacies. Eli Lilly and Company's (LLY) Trulicity™ (dulaglutide) is a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) designed with patients in mind. It comes in a single-dose pen…
11 November 2014 | By Moberg Pharma
In accordance with the resolution of the Annual General Meeting on May 13, 2014, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes to form a Nomination Committee...
11 November 2014 | By The Centre for Process Innovation
The Centre for Process Innovation (CPI) is part of a consortium which will focus on the development and scale up of nanopharmaceutical production...
11 November 2014 | By Janssen
Compared with their peers and other caregivers, carers for adults with schizophrenia report deteriorated physical and mental health and greater health resource usage/utilisation...
10 November 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced late-breaking data from the landmark ALLY Trial investigating a ribavirin-free 12-week regimen of daclatasvir (DCV) in combination with sofosbuvir (SOF) in genotype 3 hepatitis C (HCV) patients, a patient population that has emerged as one of the most difficult to treat...
10 November 2014 | By Genmab A/S
Genmab A/S announced today that the French Intergroup of Myeloma (IFM) in collaboration with Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) and Janssen Biotech, Inc. plans to start an additional Phase III study of daratumumab in frontline multiple myeloma...
10 November 2014 | By Almirall
Almirall, the global pharmaceutical company based in Barcelona, announced year to date 2014 results...
10 November 2014 | By KU Leuven
A new drug combination for rheumatoid arthritis treats the disease just as well as other intensive treatment strategies but with less medication and fewer side effects at a significantly lower cost...
10 November 2014 | By Bristol-Myers Squibb
Study results from investigational agents Opdivo (nivolumab), elotuzumab, and ulocuplumab, as well as Sprycel (dasatinib), will be highlighted...
7 November 2014 | By Sartorius
With its new BIOSTAT A, Sartorius Stedim Biotech presents a compact bioreactor | fermenter designed specifically as an entry-level model for fermentation and cell culture as well as for educational purposes...
7 November 2014 | By AstraZeneca
AstraZeneca announced that MedImmune, its global biologics research and development arm, has entered into an agreement to acquire Definiens, a privately-held company that has pioneered a world-leading imaging and data analysis technology, known as Tissue Phenomics™, which dramatically improves the identification of biomarkers in tumour tissue...
7 November 2014 | By TxCell
TxCell SA announces that Damian Marron, CEO, TxCell, will present at the 2nd Annual EU Advanced Therapies Investor Day in London...
Response from the British Generic Manufacturers Association (BGMA) to a new report issued today by the Academy of Medical Royal Colleges...
